Reuters
02 Aug 2026, 19:36 UTC · 1h ago
AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
02 Aug 2026, 19:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
AstraZeneca has been exploring a potential merger or combination deal with Bristol Myers Squibb. — A mega-merger between two pharmaceutical giants would trigger significant price volatility and revaluation for both stocks.
+0.60Which stocks this story touches
The company is exploring a potential strategic combination with a rival, which is generally viewed as a growth or consolidation opportunity.
The company is reportedly being explored as a partner in a potential merger, indicating strategic interest.
Continue reading
6 related stories
Top 1 mover · tap to explore
[mutual] The article explicitly identifies AstraZeneca and Bristol Myers Squibb as rivals.
[mutual] AstraZeneca has been exploring a deal to combine with Bristol Myers Squibb.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1h ago
